Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater

Poolbeg Pharma plc Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Market opportunity estimated to be greater than US$1 billion  Key highlights Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo modelData strengthens an...

Related Keywords

United States ,American ,Martin Kaiser ,David Allmond ,Poolbeg Pharma ,Statessaid Bispecific ,Gareth Morgan ,Institute Of Cancer Research ,Investor Meet Company ,American Cancer Society ,Advisory Board ,Key Opinion Leader ,Multiple Myeloma ,High Grade Lymphoma ,Acute Lymphoblastic Leukaemia ,Advisory Board Supportive ,Independent Advisory Board ,Key Opinion Leaders ,Product Profile ,Associate Professor ,Molecular Haematology ,Cancer Research ,Haematology Consultant ,Royal Marsden Hospital ,Chief Business Officer ,